Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging

Contrast Media and Molecular Imaging

Volumn 8, Issue 3, 2013, Pages 220-228

  Ye, Zhen ^a,b   Wu, Xueming ^a   Tan, Mingqian ^a   Jesberger, Jack ^c   Grisworld, Mark ^c   Lu, Zheng Rong ^a  

^a Case Western Reserve University   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biodegradable macromolecular MRI contrast agent; Blood pool imaging; Cancer imaging; Gd; Kinetic stability

Indexed keywords

3 (2 CARBOXYETHYLDISULFANYL)PROPANOIC ACID COPOLYMER; GADOLINIUM PENTETATE MEGLUMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BREAST TUMOR; CONTRAST ENHANCEMENT; DRUG SYNTHESIS; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERIZATION; PRIORITY JOURNAL; TUMOR XENOGRAFT; VASCULARIZATION;

ABSORBABLE IMPLANTS; AMIDES; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; DISULFIDES; FEMALE; HETEROCYCLIC COMPOUNDS; MACROMOLECULAR SUBSTANCES; MAGNETIC RESONANCE ANGIOGRAPHY; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84876809711     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1520     Document Type: Article

References (50)

1. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn Reson Imag 2007; 26(2): 235-249.
2. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imag 2002; 16(4): 407-422.
3. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for nmr imaging: theory and design. Chem Rev 1987; 87(5): 901-927.
4. Koretsky AP, Silva AC. Manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed 2004; 17(8): 527-531.
5. Hermann P, Kotek J, Kubicek V, Lukes I. Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Dalton Trans 2008; (23): 3027-3047.
6. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999; 99(9): 2293-2352.
7. Aime S, Cabella C, Colombatto S, Geninatti Crich S, Gianolio E, Maggioni F. Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J Magn Reson Imag 2002; 16(4): 394-406.
8. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imag 2009; 30(6): 1259-1267.
9. Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol 2003; 13(12): 2688-2698.
10. Schalla S, Higgins CB, Saeed M. Contrast agents for cardiovascular magnetic resonance imaging. Current status and future directions. Drugs Res Discov 2002; 3(5): 285-302.
11. Turetschek K, Floyd E, Helbich T, Roberts TP, Shames DM, Wendland MF, Carter WO, Brasch RC. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. J Magn Reson Imag 2001; 14(3): 237-242.
12. Brasch RC. Rationale and applications for macromolecular Gd-based contrast agents. Magn Reson Med 1991; 22(2): 282-287.
13. Goyen M, Shamsi K, Schoenberg SO. Vasovist-enhanced MR angiography. Eur Radiol 2006; 16(suppl 2): B9-14.
14. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 2000; 34(3): 148-155.
15. Bumb A, Brechbiel MW, Choyke P. Macromolecular and dendrimer-based magnetic resonance contrast agents. Acta Radiol 2010; 51(7): 751-767.
16. Lauffer RB, Parmelee DJ, Ouellet HS, Dolan RP, Sajiki H, Scott DM, Bernard PJ, Buchanan EM, Ong KY, Tyeklar Z, Midelfort KS, McMurry TJ, Walovitch RC. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. Acad Radiol 1996; 3(suppl 2): S356-358.
17. Barrett T, Kobayashi H, Brechbiel M, Choyke PL. Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol 2006; 60(3): 353-366.
18. Perreault P, Edelman MA, Baum RA, Yucel EK, Weisskoff RM, Shamsi K, Mohler ER, III. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology 2003; 229(3): 811-820.
19. Shamsi K, Yucel EK, Chamberlin P. A summary of safety of gadofosveset (MS-325) at 0.03mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol 2006; 41(11): 822-830.
20. Schuhmann-Giampieri G, Schmitt-Willich H, Frenzel T, Press WR, Weinmann HJ. In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging. Invest Radiol 1991; 26(11): 969-974.
21. Helbich TH, Gossman A, Mareski PA, Raduchel B, Roberts TP, Shames DM, Muhler M, Turetschek K, Brasch RC. A new polysaccharide macromolecular contrast agent for MR imaging: biodistribution and imaging characteristics. J Magn Reson Imag 2000; 11(6): 694-701.
22. Bryant LH, Jr., Brechbiel MW, Wu C, Bulte JW, Herynek V, Frank JA. Synthesis and relaxometry of high-generation (G=5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelates. J Magn Reson Imag 1999; 9(2): 348-352.
23. Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA 2001; 12(2-3): 128-134.
24. Ladd DL, Hollister R, Peng X, Wei D, Wu G, Delecki D, Snow RA, Toner JL, Kellar K, Eck J, Desai VC, Raymond G, Kinter LB, Desser TS, Rubin DL. Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties. Bioconjug Chem 1999; 10(3): 361-370.
25. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006; 35(6): 512-523.
26. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40(11): 715-724.
27. Aime S, Castelli DD, Crich SG, Gianolio E, Terreno E. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. Acc Chem Res 2009; 42(7): 822-831.
28. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, Melnyk O. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imag 1997; 7(1): 68-74.
29. Lu ZR, Ye F, Vaidya A. Polymer platforms for drug delivery and biomedical imaging. J Control Release 2007; 122(3): 269-277.
30. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008; 18(10): 2164-2173.
31. Thomsen HS, Morcos SK. Nephrogenic systemic fibrosis and nonionic linear chelates. AJR Am J Roentgenol 2007; 188(6): W580; author reply W581.
32. Lu ZR, Mohs AM, Zong Y, Feng Y. Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents. Int J Nanomed 2006; 1(1): 31-40.
33. Zong Y, Wang X, Goodrich KC, Mohs AM, Parker DL, Lu ZR. Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice. Magn Reson Med 2005; 53(4): 835-842.
34. Zong Y, Guo J, Ke T, Mohs AM, Parker DL, Lu ZR. Effect of size and charge on pharmacokinetics and in vivo MRI contrast enhancement of biodegradable polydisulfide Gd(III) complexes. J Control Release 2006; 112(3): 350-356.
35. Lu ZR, Wu X. Polydisulfide based biodegradable macromolecular magnetic resonance imaging contrast agents. Isr J Chem 2010; 50(2): 220-232.
36. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imag 2007; 26(5): 1190-1197.
37. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008; 66(2): 175-179.
38. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imag 1990; 8(4): 467-481.
39. Laurent S, Elst LV, Copoix F, Muller RN. Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol 2001; 36(2): 115-122.
40. Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 1996; 31(12): 739-742.
41. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41(3): 272-278.
42. Wu X, Zong Y, Ye Z, Lu ZR. Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats. Pharm Res 2010; 27(7): 1390-1397.
43. Lu ZR, Wang X, Parker DL, Goodrich KC, Buswell HR. Poly( l-glutamic acid) Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging. Bioconjug Chem 2003; 14(4): 715-719.
44. Xu R, Wang Y, Wang X, Jeong EK, Parker DL, Lu ZR. In vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromolecular MRI contrast agent. Exp Biol Med (Maywood) 2007; 232(8): 1081-1089.
45. Wang X, Feng Y, Ke T, Schabel M, Lu ZR. Pharmacokinetics and tissue retention of (Gd-DTPA)-cystamine copolymers, a biodegradable macromolecular magnetic resonance imaging contrast agent. Pharm Res 2005; 22(4): 596-602.
46. Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem 1995; 41(3): 361-366.
47. Deneke SM. Thiol-based antioxidants. Curr Top Cell Regul 2000; 36: 151-180.
48. Lu ZR, Parker DL, Goodrich KC, Wang X, Dalle JG, Buswell HR. Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI. Magn Reson Med 2004; 51(1): 27-34.
49. Feng Y, Zong Y, Ke T, Jeong EK, Parker DL, Lu ZR. Pharmacokinetics, biodistribution and contrast enhanced MR blood pool imaging of Gd-DTPA cystine copolymers and Gd-DTPA cystine diethyl ester copolymers in a rat model. Pharm Res 2006; 23(8): 1736-1742.
50. Zong Y, Wang X, Jeong EK, Parker DL, Lu ZR. Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents. Magn Reson Imag 2009; 27(4): 503-511.